Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Smith, H.G., Mansfield, D., Roulstone, V., Kyula-Currie, J.N., McLaughlin, M., Patel, R.R., Bergerhoff, K.F., Paget, J.T., Dillon, M.T., Khan, A., et al. (2019). PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. Clinical cancer research, Vol.25 (11), pp. 3443-3454.

Wilkins, A.C., Patin, E.C., Harrington, K.J. & Melcher, A.A. (2019). The immunological consequences of radiation‐induced DNA damage. The journal of pathology, Vol.247 (5), pp. 606-614.

Evgin, L., Huff, A.L., Kottke, T., Thompson, J., Molan, A.M., Driscoll, C.B., Schuelke, M., Shim, K.G., Wongthida, P., Ilett, E.J., et al. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer immunology research, Vol.7 (5), pp. 828-840.

Jennings, V.A., Scott, G.B., Rose, A.M., Scott, K.J., Migneco, G., Keller, B., Reilly, K., Donnelly, O., Peach, H., Dewar, D., et al. (2019). Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular therapy, Vol.27 (6), pp. 1139-1152.

Wilkins, A., McDonald, F., Harrington, K. & Melcher, A. (2019). Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. Journal for immunotherapy of cancer, Vol.7 (1).

Müller, L.M., Holmes, M., Michael, J.L., Scott, G.B., West, E.J., Scott, K.J., Parrish, C., Hall, K., Stäble, S., Jennings, V.A., et al. (2019). Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for immunotherapy of cancer, Vol.7 (1).

Khan, A.A., Paget, J.T., McLaughlin, M., Kyula, J.N., Wilkinson, M.J., Pencavel, T., Mansfield, D., Roulstone, V., Seth, R., Halle, M., et al. (2018). Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Science translational medicine, Vol.10, pp. eaar2041-eaar2041.  show abstract

Samson, A., Bentham, M.J., Scott, K., Nuovo, G., Bloy, A., Appleton, E., Adair, R.A., Dave, R., Peckham-Cooper, A., Toogood, G., et al. (2018). Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, Vol.67 (3), pp. 562-573.

Samson, A., Scott, K.J., Taggart, D., West, E.J., Wilson, E., Nuovo, G.J., Thomson, S., Corns, R., Mathew, R.K., Fuller, M.J., et al. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science translational medicine, Vol.10 (422), pp. eaam7577-eaam7577.  show abstract

Yip, K., Melcher, A., Harrington, K., Illidge, T., Nobes, J., Webster, A., Smith, D., Lorigan, P., Nathan, P. & Larkin, J., et al. (2018). Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma — Introducing the PERM Trial. Clinical oncology, Vol.30 (4), pp. 201-203.

Comins, C., Simpson, G.R., Rogers, W., Relph, K., Harrington, K., Melcher, A., Roulstone, V., Kyula, J. & Pandha, H. (2018). Synergistic antitumour effects of rapamycin and oncolytic reovirus. Cancer gene therapy, Vol.25 (5-6), pp. 148-160.

Annels, N.E., Arif, M., Simpson, G.R., Denyer, M., Moller-Levet, C., Mansfield, D., Butler, R., Shafren, D., Au, G., Knowles, M., et al. (2018). Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular therapy - oncolytics, Vol.9, pp. 1-12.

Berkeley, R.A., Steele, L.P., Mulder, A.A., van den Wollenberg, D.J., Kottke, T.J., Thompson, J., Coffey, M., Hoeben, R.C., Vile, R.G., Melcher, A., et al. (2018). Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer immunology research, Vol.6 (10), pp. 1161-1173.

Huff, A.L., Wongthida, P., Kottke, T., Thompson, J.M., Driscoll, C.B., Schuelke, M., Shim, K.G., Harris, R.S., Molan, A., Pulido, J.S., et al. (2018). APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular therapy - oncolytics, Vol.11, pp. 1-13.

Taggart, D., Andreou, T., Scott, K.J., Williams, J., Rippaus, N., Brownlie, R.J., Ilett, E.J., Salmond, R.J., Melcher, A. & Lorger, M., et al. (2018). Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc natl acad sci u s a, Vol.115 (7), pp. E1540-E1549.  show abstract

Ilett, E., Kottke, T., Thompson, J., Rajani, K., Zaidi, S., Evgin, L., Coffey, M., Ralph, C., Diaz, R., Pandha, H., et al. (2017). Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene therapy, Vol.24 (1), pp. 21-30.

Cockle, J.V., Brüning-Richardson, A., Scott, K.J., Thompson, J., Kottke, T., Morrison, E., Ismail, A., Carcaboso, A.M., Rose, A., Selby, P., et al. (2017). Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular therapy - oncolytics, Vol.5, pp. 75-86.

Kottke, T., Evgin, L., Shim, K.G., Rommelfanger, D., Boisgerault, N., Zaidi, S., Diaz, R.M., Thompson, J., Ilett, E., Coffey, M., et al. (2017). Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer immunology research, Vol.5 (11), pp. 1029-1045.

Rajani, K., Parrish, C., Kottke, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K.G., Diaz, R.-., Pandha, H., Harrington, K., et al. (2016). Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Molecular therapy, Vol.24 (1), pp. 166-174.

Mansfield, D.C., Kyula, J.N., Rosenfelder, N., Chao-Chu, J., Kramer-Marek, G., Khan, A.A., Roulstone, V., McLaughlin, M., Melcher, A.A., Vile, R.G., et al. (2016). Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene therapy, Vol.23 (4), pp. 357-368.

Cockle, J.V., Rajani, K., Zaidi, S., Kottke, T., Thompson, J., Diaz, R.M., Shim, K., Peterson, T., Parney, I.F., Short, S., et al. (2016). Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-oncology, Vol.18 (4), pp. 518-527.

Holyoake, D.L., Ward, E., Grose, D., McIntosh, D., Sebag-Montefiore, D., Radhakrishna, G., Patel, N., Silva, M., Mukherjee, S., Strauss, V.Y., et al. (2016). A phase-I trial of pre‐operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the ‘SPARC’ trial protocol. Bmc cancer, Vol.16 (1).

Kottke, T., Shim, K.G., Alonso-Camino, V., Zaidi, S., Maria Diaz, R., Pulido, J., Thompson, J., Rajani, K.R., Evgin, L., Ilett, E., et al. (2016). Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Molecular therapy - oncolytics, Vol.3.

Roulstone, V., Pedersen, M., Kyula, J., Mansfield, D., Khan, A.A., McEntee, G., Wilkinson, M., Karapanagiotou, E., Coffey, M., Marais, R., et al. (2015). BRAF- and MEK-targeted Small Molecule Inhibitors Exert Enhanced Anti-Melanoma Effects in Combination with Oncolytic Reovirus through ER Stress. Molecular therapy : the journal of the american society of gene therapy, Vol.23, pp. 931-942.  show abstract

Jebar, A.H., Vile, R.G., Melcher, A.A., Griffin, S., Selby, P.J. & Errington-Mais, F. (2015). Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of general virology, Vol.96 (7), pp. 1533-1550.

Seth, R., Khan, A.A., Pencavel, T.D., Wilkinson, M.J., Kyula, J.N., Simpson, G., Pandha, H., Melcher, A., Vile, R., Harris, P.A., et al. (2015). Adenovirally Delivered Enzyme Prodrug Therapy with Herpes Simplex Virus–Thymidine Kinase in Composite Tissue Free Flaps Shows Therapeutic Efficacy in Rat Models of Glioma. Plastic and reconstructive surgery, Vol.135, pp. 475-487.

Cockle, J.V., Picton, S., Levesley, J., Ilett, E., Carcaboso, A.M., Short, S., Steel, L.P., Melcher, A., Lawler, S.E. & Brüning-Richardson, A., et al. (2015). Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. British journal of cancer, Vol.112 (4), pp. 693-703.

Appleton, E.S., Turnbull, S., Ralph, C., West, E., Scott, K., Harrington, K., Pandha, H. & Melcher, A. (2015). Talimogene laherparepvec in the treatment of melanoma. Expert opinion on biological therapy, Vol.15 (10), pp. 1517-1530.

El-Sherbiny, Y.M., Holmes, T.D., Wetherill, L.F., Black, E.V., Wilson, E.B., Phillips, S.L., Scott, G.B., Adair, R.A., Dave, R., Scott, K.J., et al. (2015). Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cellsin vivo. Clinical & experimental immunology, Vol.180 (1), pp. 98-107.

Zaidi, S., Blanchard, M., Shim, K., Ilett, E., Rajani, K., Parrish, C., Boisgerault, N., Kottke, T., Thompson, J., Celis, E., et al. (2015). Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular therapy, Vol.23 (5), pp. 845-856.

Parrish, C., Scott, G.B., Migneco, G., Scott, K.J., Steele, L.P., Ilett, E., West, E.J., Hall, K., Selby, P.J., Buchanan, D., et al. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, Vol.29 (9), pp. 1799-1810.

Blanchard, M., Shim, K.G., Grams, M.P., Rajani, K., Diaz, R.M., Furutani, K.M., Thompson, J., Olivier, K.R., Park, S.S., Markovic, S.N., et al. (2015). Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. International journal of radiation oncology*biology*physics, Vol.93 (3), pp. 577-587.

Roulstone, V., Khan, K., Pandha, H.S., Rudman, S., Coffey, M., Gill, G.M., Melcher, A.A., Vile, R., Harrington, K.J., de Bono, J., et al. (2015). Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical cancer research, Vol.21 (6), pp. 1305-1312.

Jennings, V.A., Ilett, E.J., Scott, K.J., West, E.J., Vile, R., Pandha, H., Harrington, K., Young, A., Hall, G.D., Coffey, M., et al. (2014). Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. International journal of cancer, Vol.134 (5), pp. 1091-1101.

Alonso-Camino, V., Rajani, K., Kottke, T., Rommelfanger-Konkol, D., Zaidi, S., Thompson, J., Pulido, J., Ilett, L., Selby, P., Pandha, H., et al. (2014). The Profile of Tumor Antigens Which Can Be Targeted By Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular therapy, Vol.22, pp. S200-S200.

Ilett, E., Kottke, T., Donnelly, O., Thompson, J., Willmon, C., Diaz, R., Zaidi, S., Coffey, M., Selby, P., Harrington, K., et al. (2014). Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular therapy, Vol.22 (10), pp. 1851-1863.

Alonso-Camino, V., Rajani, K., Kottke, T., Rommelfanger-Konkol, D., Zaidi, S., Thompson, J., Pulido, J., Ilett, E., Donnelly, O., Selby, P., et al. (2014). The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular therapy, Vol.22 (11), pp. 1936-1948.

Donnelly, O.G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V., Scott, K., Peach, H., Phillips, R.M., Bond, J., Pandha, H., et al. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene therapy, Vol.20 (1), pp. 7-15.

Mansfield, D., Pencavel, T., Kyula, J.N., Zaidi, S., Roulstone, V., Thway, K., Karapanagiotou, L., Khan, A.A., McLaughlin, M., Touchefeu, Y., et al. (2013). Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral oncology, Vol.49, pp. 108-118.  show abstract

Kyula, J.N., Khan, A.A., Mansfield, D., Karapanagiotou, E.M., McLaughlin, M., Roulstone, V., Zaidi, S., Pencavel, T., Touchefeu, Y., Seth, R., et al. (2013). Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/E BRAF mutant melanoma depends on JNK and TNF-alpha signaling. Oncogene, Vol.33, pp. 1-13.  show abstract

Roulstone, V., Twigger, K., Zaidi, S., Pencavel, T., Kyula, J.N., White, C., McLaughlin, M., Seth, R., Karapanagiotou, E.M., Mansfield, D., et al. (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy. Gene therapy, Vol.20 (5), pp. 521-528.

Cockle, J.V., Picton, S.V. & Melcher, A. (2013). Future clinical potential of oncolytic virotherapy for pediatric CNS tumors. Cns oncology, Vol.2 (4), pp. 307-310.

Donnelly, O., Harrington, K., Melcher, A. & Pandha, H. (2013). Live viruses to treat cancer. Journal of the royal society of medicine, Vol.106 (8), pp. 310-314.

Boisgerault, N., Kottke, T., Pulido, J., Thompson, J., Diaz, R.M., Rommelfanger-Konkol, D., Embry, A., Saenz, D., Poeschla, E., Pandha, H., et al. (2013). Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Molecular therapy, Vol.21 (8), pp. 1507-1516.

Kottke, T., Boisgerault, N., Diaz, R.M., Donnelly, O., Rommelfanger-Konkol, D., Pulido, J., Thompson, J., Mukhopadhyay, D., Kaspar, R., Coffey, M., et al. (2013). Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature medicine, Vol.19 (12), pp. 1625-1631.

Adair, R.A., Scott, K.J., Fraser, S., Errington-Mais, F., Pandha, H., Coffey, M., Selby, P., Cook, G.P., Vile, R., Harrington, K.J., et al. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. International journal of cancer, Vol.132 (10), pp. 2327-2338.

Tai, L.-., Zhang, J., Scott, K.J., de Souza, C.T., Alkayyal, A.A., Ananth, A.A., Sahi, S., Adair, R.A., Mahmoud, A.B., Sad, S., et al. (2013). Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells. Clinical cancer research, Vol.19 (18), pp. 5104-5115.

Karapanagiotou, E.M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M.E., Larkin, J., Syrigos, K.N., et al. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical cancer research, Vol.18 (7), pp. 2080-2089.

Simpson, G.R., Horvath, A., Annels, N.E., Pencavel, T., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, R.S., Mostafid, H., et al. (2012). Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British journal of cancer, Vol.106 (3), pp. 496-507.

G. Donnelly, O., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R. & A. Melcher, A. (2012). Recent Clinical Experience with Oncolytic Viruses. Current pharmaceutical biotechnology, Vol.13 (9), pp. 1834-1841.

Pulido, J., Kottke, T., Thompson, J., Galivo, F., Wongthida, P., Diaz, R.M., Rommelfanger, D., Ilett, E., Pease, L., Pandha, H., et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature biotechnology, Vol.30 (4), pp. 337-343.

Nuovo, G.J., Garofalo, M., Valeri, N., Roulstone, V., Volinia, S., Cohn, D.E., Phelps, M., Harrington, K.J., Vile, R., Melcher, A., et al. (2012). Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern pathology, Vol.25 (10), pp. 1333-1344.

Donnelly, O., Vile, R., Pandha, H., Harrington, K. & Melcher, A. (2012). The Hitchhiker’s Guide to Virotherapy. Oncotarget, Vol.3 (8).

Twigger, K., Roulstone, V., Kyula, J., Karapanagiotou, E.M., Syrigos, K.N., Morgan, R., White, C., Bhide, S., Nuovo, G., Coffey, M., et al. (2012). Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. Bmc cancer, Vol.12 (1).

Adair, R.A., Roulstone, V., Scott, K.J., Morgan, R., Nuovo, G.J., Fuller, M., Beirne, D., West, E.J., Jennings, V.A., Rose, A., et al. (2012). Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. Science translational medicine, Vol.4 (138), pp. 138ra77-138ra77.

Ilett, E.J., Barcena, M., Errington-Mais, F., Griffin, S., Harrington, K.J., Pandha, H.S., Coffey, M., Selby, P.J., Limpens, R.W., Mommaas, M., et al. (2011). Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization. Clin cancer res, Vol.17 (9), pp. 2767-2776.  show abstract

Willmon, C., Diaz, R.M., Wongthida, P., Galivo, F., Kottke, T., Thompson, J., Albelda, S., Harrington, K., Melcher, A. & Vile, R., et al. (2011). Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. Mol ther, Vol.19 (1), pp. 140-149.  show abstract

Heinemann, L., Simpson, G.R., Boxall, A., Kottke, T., Relph, K.L., Vile, R., Melcher, A., Prestwich, R., Harrington, K.J., Morgan, R., et al. (2011). Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. Bmc cancer, Vol.11,  show abstract

Kottke, T., Errington, F., Pulido, J., Galivo, F., Thompson, J., Wongthida, P., Diaz, R.M., Chong, H., Ilett, E., Chester, J., et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat med, Vol.17 (7), pp. 854-U223.  show abstract

West, E.J., Scott, K.J., Jennings, V.A. & Melcher, A.A. (2011). Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. British journal of cancer, Vol.105 (6), pp. 787-795.

Kottke, T., Chester, J., Ilett, E., Thompson, J., Diaz, R., Coffey, M., Selby, P., Nuovo, G., Pulido, J., Mukhopadhyay, D., et al. (2011). Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy. Mol ther, Vol.19 (10), pp. 1802-1812.  show abstract

Steele, L., Errington, F., Prestwich, R., Ilett, E., Harrington, K., Pandha, H., Coffey, M., Selby, P., Vile, R. & Melcher, A., et al. (2011). Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappa B mediated and supports innate and adaptive anti-tumour immune priming. Mol cancer, Vol.10,  show abstract

Harrington, K.J., Karapanagiotou, E.M., Roulstone, V., Twigger, K.R., White, C.L., Vidal, L., Beirne, D., Prestwich, R., Newbold, K., Ahmed, M., et al. (2010). Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clin cancer res, Vol.16 (11), pp. 3067-3077.  show abstract

Hingorani, M., Spitzweg, C., Vassaux, G., Newbold, K., Melcher, A., Pandha, H., Vile, R. & Harrington, K. (2010). The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery. Curr cancer drug tar, Vol.10 (2), pp. 242-267.  show abstract

Harrington, K.J., Vile, R.G., Melcher, A., Chester, J. & Pandha, H.S. (2010). Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine growth f r, Vol.21 (2-3), pp. 91-98.  show abstract

Pencavel, T., Seth, R., Hayes, A., Melcher, A., Pandha, H., Vile, R. & Harrington, K.J. (2010). Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. Gene ther, Vol.17 (8), pp. 949-960.  show abstract

Hingorani, M., White, C.L., Zaidi, S., Pandha, H.S., Melcher, A.A., Bhide, S.A., Nutting, C.M., Syrigos, K.N., Vile, R.G., Vassaux, G., et al. (2010). Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair. Mol ther, Vol.18 (9), pp. 1599-1605.  show abstract

Kottke, T., Hall, G., Pulido, J., Diaz, R.M., Thompson, J., Chong, H., Selby, P., Coffey, M., Pandha, H., Chester, J., et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J clin invest, Vol.120 (5), pp. 1551-1560.  show abstract

Heinemann, L., Simpson, G.R., Annels, N.E., Vile, R., Melcher, A., Prestwich, R., Harrington, K.J. & Pandha, H.S. (2010). The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis. Mol ther, Vol.18 (12), pp. 2085-2093.  show abstract

Comins, C., Spicer, J., Protheroe, A., Roulstone, V., Twigger, K., White, C.M., Vile, R., Melcher, A., Coffey, M.C., Mettinger, K.L., et al. (2010). REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clin cancer res, Vol.16 (22), pp. 5564-5572.  show abstract

Kottke, T., Pulido, J., Thompson, J., Sanchez-Perez, L., Chong, H., Calderwood, S.K., Selby, P., Harrington, K., Strome, S.E., Melcher, A., et al. (2009). Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70-Mediated Inflammatory Killing of Normal Pancreas. Cancer res, Vol.69 (19), pp. 7767-7774.  show abstract

Pandha, H.S., Heinemann, L., Simpson, G.R., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, K.J. & Morgan, R. (2009). Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. Clin cancer res, Vol.15 (19), pp. 6158-6166.  show abstract

Agrawal, V.K., Copeland, K.M., Barbachano, Y., Rahim, A., Seth, R., White, C.L., Hingorani, M., Nutting, C.M., Kelly, M., Harris, P., et al. (2009). Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene ther, Vol.16 (1), pp. 78-92.  show abstract

Prestwich, R.J., Errington, F., Steele, L.P., Ilett, E.J., Morgan, R.S., Harrington, K.J., Pandha, H.S., Selby, P.J., Vile, R.G. & Melcher, A.A., et al. (2009). Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus. J immunol, Vol.183 (7), pp. 4312-4321.  show abstract

Prestwich, R.J., Ilett, E.J., Errington, F., Diaz, R.M., Steele, L.P., Kottke, T., Thompson, J., Galivo, F., Harrington, K.J., Pandha, H.S., et al. (2009). Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. Clin cancer res, Vol.15 (13), pp. 4374-4381.  show abstract

West, E., Morgan, R., Scott, K., Merrick, A., Lubenko, A., Pawson, D., Selby, P., Hatfield, P., Prestwich, R., Fraser, S., et al. (2009). Clinical Grade OK432-activated Dendritic Cells. Journal of immunotherapy, Vol.32 (1), pp. 66-78.

Prestwich, R.J., Scott, K.J., Brown, J., Harnden, P., Whelan, P., Cartledge, J., O’Donnell, D., Pandha, H.S., Selby, P.J., Banks, R.E., et al. (2009). The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. Bju international, Vol.103 (6), pp. 740-746.

Ilett, E.J., Prestwich, R.J., Kottke, T., Errington, F., Thompson, J.M., Harrington, K.J., Pandha, H.S., Coffey, M., Selby, P.J., Vile, R.G., et al. (2009). Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene ther, Vol.16 (5), pp. 689-699.  show abstract

Pandha, H., Melcher, A., Harrington, K. & Vile, R. (2009). Oncolytic Viruses: Time to Compare, Contrast, and Combine?. Mol ther, Vol.17 (6), pp. 934-935.

Pandha, H., Melcher, A., Harrington, K. & Vile, R. (2009). Oncolytic Viruses: Time to Compare, Contrast, and Combine?. Molecular therapy, Vol.17 (6), pp. 934-935.

Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A. & Vile, R. (2009). Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy. Mol ther, Vol.17 (10), pp. 1667-1676.  show abstract

Prestwich, R.J., Errington, F., Diaz, R.M., Pandha, H.S., Harrington, K.J., Melcher, A.A. & Vile, R.G. (2009). The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon. Hum gene ther, Vol.20 (10), pp. 1119-1132.  show abstract

Kottke, T., Thompson, J., Diaz, R.M., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, R.G., et al. (2009). Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clin cancer res, Vol.15 (2), pp. 561-569.  show abstract

Saunders, M., Anthoney, A., Coffey, M., Mettinger, K., Thompson, B., Melcher, A., Nutting, C.M. & Harrington, K. (2009). Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J clin oncol, Vol.27 (15_suppl), p. e14514.  show abstract

Karapanagiotou, E., Pandha, H.S., Hall, G., Chester, J., Melcher, A., Coffey, M., de Bono, J., Gore, M.E., Nutting, C.M. & Harrington, K.J., et al. (2009). Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. J clin oncol, Vol.27 (15_suppl), p. e14519.  show abstract

Qiao, J., Wang, H.X., Kottke, T., White, C., Twigger, K., Diaz, R.M., Thompson, J., Selby, P., de Bono, J., Melcher, A., et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin cancer res, Vol.14 (1), pp. 259-269.  show abstract

Twigger, K., Vidal, L., White, C.L., De Bono, J.S., Bhide, S., Coffey, M., Thompson, B., Vile, R.G., Heinemann, L., Pandha, H.S., et al. (2008). Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin cancer res, Vol.14 (3), pp. 912-923.  show abstract

Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, R.M., Thompson, J., Ryno, P., Barber, G.N., Chester, J., et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat med, Vol.14 (1), pp. 37-44.  show abstract

Hingorani, M., White, C.L., Merron, A., Peerlinck, I., Gore, M.E., Slade, A., Scott, S.D., Nutting, C.M., Pandha, H.S., Melcher, A.A., et al. (2008). Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. Cancer res, Vol.68 (23), pp. 9771-9778.  show abstract

Vidal, L., Pandha, H.S., Yap, T.A., White, C.L., Twigger, K., Vile, R.G., Melcher, A., Coffey, M., Harrington, K.J. & DeBono, J.S., et al. (2008). A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clin cancer res, Vol.14 (21), pp. 7127-7137.  show abstract

Errington, F., Steele, L., Prestwich, R., Harrington, K.J., Pandha, H.S., Vidal, L., de Bono, J., Selby, P., Coffey, M., Vile, R., et al. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. J immunol, Vol.180 (9), pp. 6018-6026.  show abstract

Hingorani, M., White, C.L., Zaidi, S., Merron, A., Peerlinck, I., Gore, M.E., Nutting, C.M., Pandha, H.S., Melcher, A.A., Vile, R.G., et al. (2008). Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: Implications for sodium iodide symporter gene therapy. Clin cancer res, Vol.14 (15), pp. 4915-4924.  show abstract

Hill, K.S., Errington, F., Steele, L.P., Merrick, A., Morgan, R., Selby, P.J., Georgopoulos, N.T., O'Donnell, D.M. & Melcher, A.A. (2008). OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions. The journal of immunology, Vol.181 (5), pp. 3108-3115.

Prestwich, R.J., Errington, F., Harrington, K.J., Pandha, H.S., Selby, P. & Melcher, A. (2008). Oncolytic viruses: do they have a role in anti-cancer therapy?. Clinical medicine. oncology, Vol.2, pp. 83-96.  show abstract  full text

White, C.L., Menghistu, T., Twigger, K.R., Searle, P.F., Bhide, S.A., Vile, R.G., Melcher, A.A., Pandha, H.S. & Harrington, K.J. (2008). Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene ther, Vol.15 (6), pp. 424-433.  show abstract

Prestwich, R.J., Errington, F., Hatfield, P., Merrick, A.E., Ilett, E.J., Selby, P.J. & Melcher, A.A. (2008). The Immune System — is it Relevant to Cancer Development, Progression and Treatment?. Clinical oncology, Vol.20 (2), pp. 101-112.

White, C.L., Twigger, K.R., Vidal, L., De Bono, J.S., Coffey, M., Heinemann, L., Morgan, R., Merrick, A., Errington, F., Vile, R.G., et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene ther, Vol.15 (12), pp. 911-920.  show abstract

Merrick, A., Diaz, R.M., O’Donnell, D., Selby, P., Vile, R. & Melcher, A. (2008). Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy. Cancer immunology, immunotherapy, Vol.57 (6), pp. 897-906.

Kottke, T., Galivo, F., Wongthida, P., Diaz, R.M., Thompson, J., Jevremovic, D., Barber, G.N., Hall, G., Chester, J., Selby, P., et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol ther, Vol.16 (7), pp. 1217-1226.  show abstract

Prestwich, R.J., Harrington, K.J., Vile, R.G. & Melcher, A.A. (2008). Immunotherapeutic potential of oncolytic virotherapy. Lancet oncol, Vol.9 (7), pp. 610-612.

Kottke, T., Galivo, F., Wongthida, P., Maria Diaz, R., Thompson, J., Jevremovic, D., Barber, G.N., Hall, G., Chester, J., Selby, P., et al. (2008). Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Mol ther, Vol.16 (7), pp. 1217-1226.  show abstract

Harrington, K.J., Melcher, A., Vassaux, G., Pandha, H.S. & Vile, R.G. (2008). Exploiting synergies between radiation and oncolytic viruses. Curr opin mol ther, Vol.10 (4), pp. 362-370.  show abstract

Comins, C., Heinemann, L., Harrington, K., Melcher, A., De Bono, J. & Pandha, H. (2008). Reovirus: Viral therapy for cancer 'as nature intended'. Clin oncol-uk, Vol.20 (7), pp. 548-554.  show abstract

Errington, F., White, C.L., Twigger, K.R., Rose, A., Scott, K., Steele, L., Ilett, L.J., Prestwich, R., Pandha, H.S., Coffey, M., et al. (2008). Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene ther, Vol.15 (18), pp. 1257-1270.  show abstract

Hatfield, P., Merrick, A.E., West, E., OʼDonnell, D., Selby, P., Vile, R. & Melcher, A.A. (2008). Optimization of Dendritic Cell Loading With Tumor Cell Lysates for Cancer Immunotherapy. Journal of immunotherapy, Vol.31 (7), pp. 620-632.

Prestwich, R.J., Harrington, K.J., Pandha, H.S., Vile, R.G., Melcher, A.A. & Errington, F. (2008). Oncolytic viruses: a novel form of immunotherapy. Expert rev anticanc, Vol.8 (10), pp. 1581-1588.  show abstract

Kottke, T., Diaz, R.M., Kaluza, K., Pulido, J., Galivo, F., Wongthida, P., Thompson, J., Willmon, C., Barber, G.N., Chester, J., et al. (2008). Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer. Mol ther, Vol.16 (12), pp. 1910-1918.  show abstract

Prestwich, R.J., Errington, F., Ilett, E.J., Morgan, R.S., Scott, K.J., Kottke, T., Thompson, J., Morrison, E.E., Harrington, K.J., Pandha, H.S., et al. (2008). Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity. Clin cancer res, Vol.14 (22), pp. 7358-7366.  show abstract

Hingorani, M., White, C., Agrawal, V., Vidal, L., Melcher, A. & Harrington, K. (2007). Combining Radiation and Cancer Gene Therapy: A Potential Marriage of Physical and Biological Targeting?. Current cancer drug targets, Vol.7 (4), pp. 389-409.

Craven, I., Crellin, A., Cooper, R., Melcher, A., Byrne, P. & Sebag-Montefiore, D. (2007). Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. British journal of cancer, Vol.97 (10), pp. 1333-1337.

Harris, D., Vidal, L., Melcher, A., Newbold, K., Anthony, A., Karavasilis, V., Agarwal, R., White, C., Twigger, K., Coffey, M., et al. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. Mol cancer ther, Vol.6 (12), pp. 3458S-3458S.

Kottke, T., Sanchez-Perez, L., Diaz, R.M., Thompson, J., Chong, H., Harrington, K., Calderwood, S.K., Pulido, J., Georgopoulos, N., Selby, P., et al. (2007). Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer res, Vol.67 (24), pp. 11970-11979.  show abstract

Georgopoulos, N.T., Merrick, A., Scott, N., Selby, P.J., Melcher, A. & Trejdosiewicz, L.K. (2007). CD40-mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing. International journal of cancer, Vol.121 (6), pp. 1373-1381.

Errington, F., Jones, J., Merrick, A., Bateman, A., Harrington, K., Gough, M., O'Donnell, D., Selby, P., Vile, R. & Melcher, A., et al. (2006). Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene ther, Vol.13 (2), pp. 138-149.  show abstract

Errington, F., Bateman, A., Kottke, T., Thompson, J., Harrington, K., Merrick, A., Hatfield, P., Selby, P., Vile, R. & Melcher, A., et al. (2006). Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin cancer res, Vol.12 (4), pp. 1333-1341.  show abstract

Hatfield, P., Merrick, A., Harrington, K., Vile, R., Bateman, A., Selby, P. & Melcher, A. (2005). Radiation-induced cell death and dendritic cells: Potential for cancer immunotherapy?. Clin oncol-uk, Vol.17 (1), pp. 1-11.  show abstract

Merrick, A., Errington, F., Milward, K., O'Donnell, D., Harrington, K., Bateman, A., Pandha, H., Vile, R., Morrison, E., Selby, P., et al. (2005). Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Brit j cancer, Vol.92 (8), pp. 1450-1458.  show abstract

Daniels, G.A., Sanchez-Perez, L., Diaz, R.M., Kottke, T., Thompson, J., Lai, M.Y., Gough, M., Karim, M., Bushell, A., Chong, H., et al. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nat biotechnol, Vol.22 (9), pp. 1125-1132.  show abstract

Melcher, A.A. & Sebag-Montefiore, D. (2003). Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. British journal of cancer, Vol.88 (9), pp. 1352-1357.

Linardakis, E., Bateman, A., Phan, V., Ahmed, A., Gough, M., Olivier, K., Kennedy, R., Errington, F., Harrington, K.J., Melcher, A., et al. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer res, Vol.62 (19), pp. 5495-5504.  show abstract

Harrington, K.J., Bateman, A.R., Melcher, A.A., Ahmed, A. & Vile, R.G. (2002). Cancer gene therapy: Part 1 Vector development and regulation of gene expression. Clin oncol-uk, Vol.14 (1), pp. 3-16.

Harrington, K.J., Melcher, A.A., Bateman, A.R., Ahmed, A. & Vile, R.G. (2002). Cancer gene therapy: Part 2 Candidate transgenes and their clinical development. Clin oncol-uk, Vol.14 (2), pp. 148-169.

Melcher, A., Bateman, A., Harrington, K., Ahmed, A., Gough, M. & Vile, R. (2002). Dendritic Cells for the Immunotherapy of Cancer. Clinical oncology, Vol.14 (3), pp. 185-192.

Turnbull, S., West, E., Scott, K., Appleton, E., Melcher, A. & Ralph, C. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. Viruses, Vol.7 (12), pp. 6291-6312.

Bradley, S., Jakes, A., Harrington, K., Pandha, H., Melcher, A. & Errington-Mais, F. Applications of coxsackievirus A21 in oncology. Oncolytic virotherapy, , pp. 47-47.

Pandha, H., Simpson, G., Relph, K., Melcher, A. & Harrington, K. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic virotherapy, , pp. 1-1.

Somaiah, N., Wilkins, A. & Melcher, A. Science in Focus; Biological optimisation of radiotherapy fraction. Clinical oncology, .

Gonzalez-Exposito, R., Semiannikova, M., Griffiths, B., Khan, K., Barber, L., Woolston, A., Spain, G., von Loga, K., Challoner, B., Patel, R., et al. CEA Expression Heterogeneity and Plasticity Confer Resistance to the CEA-Targeting Bispecific Immunotherapy Antibody Cibisatamab (CEA-TCB) in Patient-Derived Colorectal Cancer Organoids. Journal for immunotherapy of cancer, .  show abstract

Annels, N.E., Mansfield, D., Arif, M., Ballesteros-Merino, C., Simpson, G.R., Denyer, M., Sandhu, S.S., Melcher, A., Harrington, K.J., Davies, B., et al. Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21. Clinical cancer research, , pp. clincanres.4022.2018-clincanres.4022.2018.

Dillon, M. ATR inhibition potentiates the radiation induced inflammatory tumor microenvironment. Clinical cancer research, .


Conferences

Sadanandam, A., Young, K., Lawlor, R., Patil, Y., Ragulan, C., Luchini, C., Cantu, C., Mansfield, D., Melcher, A., Cunningham, D., et al. (2019). Immune Characteristics of Pancreatic Neuroendocrine Tumors According to Grade and Molecular Subtypes, NEUROENDOCRINOLOGY, Vol.108, p.34.

Pandha, H.S., Harrington, K.J., Ralph, C., Melcher, A., Mansfield, D., Grose, M., Davies, B., Karpathy, R. & Shafren, D. (2016). Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients., Journal of Clinical Oncology, Vol.34 (15_suppl), p.TPS3108.

Pandha, H.S., Annels, N.E., Simpson, G., Mostafid, H., Harrington, K.J., Melcher, A., Grose, M., Davies, B., Au, G.G., Karpathy, R., et al. (2016). Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21., Journal of Clinical Oncology, Vol.34 (15_suppl), p.e16016.

Rajani, K., Parrish, C., Shim, K., Ilett, L., Errington-Mais, F., Thompson, J., Kottke, T., Maria-Diaz, R., Selby, P., Pandha, H., et al. (2015). Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Immunology, .

Pandha, H., Harrington, K., Ralph, C., Melcher, A. & Shafren, D.R. (2015). Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Clinical Trials, .

Rajani, K., Shim, K., Parrish, C., Ilett, L., Kottke, T., Pulido, J., Thompson, J., Pandha, H., Harrington, K., Melcher, A., et al. (2015). 69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses, Molecular Therapy, Vol.23, p.S30.

Simpson, G.R., Ajaz, M., Launchbury, F.A., Bolton, G., Melcher, A.A., Harrington, K.J., Au, G.G., Shafren, D.R. & Pandha, H.S. (2014). Major synergy between Coxsackievirus A21 (CAVATAK (TM)) and radiotherapy or chemotherapy in bladder cancer, HUMAN GENE THERAPY, Vol.25 (12), p.A13.

Jebar, A., Bentham, M., Errington-Mais, F., Scott, K., Peckham-Cooper, A., Dave, R., Toogood, G., Swinson, D., Ralph, C., Anthoney, A., et al. (2014). Combined anti-viral and anti-tumour therapy for virus-associated liver cancer, HUMAN GENE THERAPY, Vol.25 (12), p.A27.

Ilett, E., Kottke, T., Donnelly, O., Thompson, J., Willmon, C., Diaz, R., Zaidi, S., Coffey, M., Selby, P., Harrington, K., et al. (2014). Direct, Cytokine-Conditioned, In Vivo Cell Loading for Systemic Delivery of Oncolytic Viruses, MOLECULAR THERAPY, Vol.22, p.S245.

Zaidi, S., Blanchard, M., Shim, K., Ilett, E., Kottke, T., Thompson, J., Celis, E., Pandha, H., Selby, P., Melcher, A., et al. (2014). Acquisition of Mutated BRAF Is as a Major Effector of Melanoma Recurrence Which Can Be Targeted By Immuno- or Chemo-Therapy, MOLECULAR THERAPY, Vol.22, p.S245.

Simpson, G.R., Annels, N., Ajaz, M., Launchbury, F., Bolton, G., Melcher, A.A., Harrington, K.J., Au, G., Shafren, D. & Pandha, H., et al. (2014). 118 Major synergy between Coxsackievirus A21 (CAVATAK™) and radiotherapy or chemotherapy in bladder cancer, European Journal of Cancer, Vol.50, pp.41-42.

Jebar, A., West, E., Scott, K., Thomson, S., Corns, R., Coffey, M.C., Rose, A., Nuovo, G., Ryan, M., Errington-Mais, F., et al. (2014). Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients., Journal of Clinical Oncology, Vol.32 (15_suppl), p.3104.

Kottke, T., Donnelly, O., Ilett, E., Thompson, J., Diaz, R., Coffey, M., Selby, P., Pandha, H., Harrington, K., Melcher, A., et al. (2013). In Vivo Expansion of a Recipient Population of Cell Carriers Allows for Highly Effective Systemic Delivery of Oncolytic Reovirus Even in the Presence of Neutralizing Antibody, MOLECULAR THERAPY, Vol.21, p.S7.

Kottke, T., Donnelly, O., Boisgerault, N., Diaz, R., Rommelfanger-Konkol, D., Pulido, J., Thompson, J., Mukhopadhyay, D., Knutson, K., Behrens, M., et al. (2013). Tumor Relapse Is Associated with an Innate Immune Resistant Phenotype across Tumor and Treatment Types Which Can Be Targeted with Rational Second Line Therapies, MOLECULAR THERAPY, Vol.21, p.S249.

Boisgerault, N., Pulido, J., Kottke, T., Donnelly, O., Celis, E., Thompson, J., Diaz, R., Harrington, K., Pandha, H., Selby, P., et al. (2013). Tumor Recurrences Share Immunogenic Antigens across Both Tumor Types and Primary Treatments Which Can Be Therapeutically Targeted with VSV-cDNA Libraries, MOLECULAR THERAPY, Vol.21, p.S152.

Kottke, T., Donnelly, O., Boisgerault, N., Diaz, R., Thompson, J., Chester, J., Pandha, H., Harrington, K., Melcher, A. & Vile, R., et al. (2012). Characterization of the Mechanisms of Tumor Dormancy and Recurrence Following Front Line Immuno-, Viro- or Suicide Gene-, Therapy, MOLECULAR THERAPY, Vol.20, p.S268.

Kottke, T., Thompson, J., Diaz, R.M., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, R.G., et al. (2009). Targeting the Tumor Vasculature To Enhance Systemic Delivery of Oncolytic Viruses, Presented at 12th Annual Meeting of the American Society of Gene Therapy, San Diego, CA. MOLECULAR THERAPY, Vol.17, p.S158.

Kottke, T., Pulido, J., Thompson, J., Sanchez-Perez, L., Chong, H., Calderwood, S.K., Dong, H.D., Pease, L., Selby, P., Harrington, K., et al. (2009). Inflammatory Killing of the Pancreas Induces Multiple Immune Checkpoints Which Protect from Autoimmunity but Which Can Be Manipulated To Achieve Anti Tumor Immunity, Presented at 12th Annual Meeting of the American Society of Gene Therapy, San Diego, CA. MOLECULAR THERAPY, Vol.17, p.S154.

Ilett, E., Prestwich, R., Kottke, T., Thompson, J., Willmon, C., Coffey, M., Selby, P., Harrington, K., Melcher, A. & Vile, R.G., et al. (2009). Cell Carrier-Mediated Protection Allows for Systemic Delivery of Oncolytic Viruses in Virus-Immune Hosts, Presented at 12th Annual Meeting of the American Society of Gene Therapy, San Diego, CA. MOLECULAR THERAPY, Vol.17, p.S300.

Saunders, M., Anthoney, A., Coffey, M., Mettinger, K., Thompson, B., Melcher, A., Nutting, C.M. & Harrington, K. (2009). Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Heinemann, L., Simpson, G., Harrington, K., Melcher, A., Coffey, M.C. & Pandha, H.S. (2008). Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model, Presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, SWITZERLAND. EJC SUPPLEMENTS, Vol.6 (12), p.99.

Kottke, T., Thompson, J., Diaz, R.M., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, R., et al. (2008). Systemic delivery of oncolytic vectors to treat metastatic disease, Presented at 16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, BELGIUM. HUMAN GENE THERAPY, Vol.19 (10), p.1063.

Heinemann, L., Kottke, T., Vile, R., Coffey, M.C., Harrington, K., Melcher, A. & Pandha, H.S. (2008). Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model, Presented at 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer, San Diego, CA. JOURNAL OF IMMUNOTHERAPY, Vol.31 (9), pp.951-952.

O'Connell, M., Mortimer, P.S., Melcher, A. & Layton, A.M. (2007). Diagnosis and management of cutaneous side-effects in patients receiving treatment based on epidermal growth factor blockade, BRITISH JOURNAL OF DERMATOLOGY, Vol.157, p.3.

Daniels, G., Sanchez-Perez, L., Kottke, T., Diaz, R.M., Thompson, J., Lai, M., Gough, M., Karim, M., Bushell, A., Chong, H., et al. (2004). Intentional killing of normal nelanocytes by gene transfer generates curative anti melanoma immunity without obligate autoimmunity, Presented at 7th Annual Meeting of the American-Society-of-Gene-Therapy, Minneapolis, MN. MOLECULAR THERAPY, Vol.9, pp.S134-S135.